Articles related to POLYENDOCRINE METABOLIC OVARIAN SYNDROME (PMOS)

Following a 14-year international consensus effort involving 56 professional and patient organizations, polycystic ovary syndrome is being renamed polyendocrine metabolic ovarian syndrome, with full guideline incorporation expected by 2028.

An international consensus involving more than 14,000 patients and health professionals renamed polycystic ovary syndrome to polyendocrine metabolic ovarian syndrome (PMOS) to reflect its endocrine and metabolic features.

A clinical review outlines how OBGYNs can integrate GLP-1 receptor agonist therapy into obesity care for women of reproductive age, with attention to fertility, contraception, and adherence.

The 2023 PCOS guideline update strengthens the recognition of PCOS as a complex condition with far-reaching health implications, emphasizing the need for a multidisciplinary approach to care.

This study sheds light on the cognitive challenges associated with PCOS, revealing that women with the condition may face significant cognitive performance gaps. Understanding these associations is crucial for developing targeted interventions and support mechanisms for patients.